The lead investigator gave the author of a Seeking Alpha article trial patient's comments.
So I don't think there is any FDA regulation preventing patients/caregivers from talking.
Only 30 patients going forward. Two discontinued treatment unrelated to study drug (page 7 of November presentation).
It was not useless, the trial was designed for safety and dosage.
Problem is they're implying efficacy, which can't be determined at this stage.
Why should the Alzheimer's Organization care what's being said about a specific company or their drug?
"If not, however, a complete lack of clinical-stage candidates to fall back on could result in heavy losses. With the extremely limited clinical data to base a decision on, it's hardly worth the risk."
They have stated that the next step is a pivotal phase IIb/III trial so Anavex 2-73 won't be approved based upon results from the current trial.
Very unlikely that the FDA will tentative approve a drug for millions based upon results from a safety / dose finding study of 32 patients.
Also, the phase 2A (Part B) extension will not be completed until late September (52 weeks from final enrollment), so commercialization is not happening in six months.
"Losing 50% in a single day is unfathomable"
Welcome to Biotech investing.
PS: I lost 70% in one day on CLVS.
No mention from company about adding patients, so I'll assume they were not replaced with new patients.
Also, since they discontinued treatment, their data would be excluded.
As far as I know, the Anavex 2-73 trial continues unabated despite the criticism of certain individuals.
I don't think the Alzheimer's Association cares about the ongoing battle between supporters and critics.
I think they care about whether the drug is going to help patients.